美国血液学会2020年指南:老年新诊断急性髓系白血病的治疗
美国血液学会(ASH)组建多学科指南小组,基于截至2019年5月24日的系统证据评价,采用GRADE方法针对老年急性髓系白血病(AML)管理的6个关键问题制定循证推荐,包括治疗与最佳支持治疗的选择、治疗强度、缓解后治疗、联合与单药诱导、低强度治疗时长及输血支持。推荐治疗优于最佳支持治疗,耐受时推荐更强治疗,并强调全程医患沟通以持续明确治疗目标与风险获益平衡。
要点
- 推荐对老年AML患者进行治疗,而非仅最佳支持治疗。
- 当患者可耐受时,推荐更强治疗而非更弱治疗。
- 全程需医患持续沟通,动态明确治疗目标与风险获益平衡。
核心结论
- 推荐治疗优于最佳支持治疗,耐受时推荐更强治疗,但需以全程医患沟通持续明确治疗目标和风险获益平衡为原则。
研究设计与样本
- ASH组建多学科指南小组,由McMaster GRADE中心支持,系统证据评价检索至2019年5月24日,采用GRADE及Evidence-to-Decision框架形成推荐并公开征求意见。
主要发现
- 小组就老年AML管理的6个关键问题达成推荐:治疗与最佳支持治疗的选择、治疗强度、缓解后治疗的作用与时长、诱导及后续联合与单药、低强度治疗时长、不再接受抗白血病治疗患者的输血支持。
关键数值与推荐
- 推荐治疗而非最佳支持治疗。
- 当认为可耐受时,推荐更强治疗而非更弱治疗。
临床怎么用
- 在患者整个疾病过程中,临床医生与患者应持续讨论并明确治疗目标及治疗的相对风险获益平衡。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Older adults with acute myeloid leukemia (AML) represent a vulnerable population in whom disease-based and clinical risk factors, patient goals, prognosis, and practitioner- and patient-perceived treatment risks and benefits influence treatment recommendations. OBJECTIVE: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about management of AML in older adults. METHODS: ASH formed a multidisciplinary guideline panel that included specialists in myeloid leukemia, geriatric oncology, patient-reported outcomes and decision-making, frailty, epidemiology, and methodology, as well as patients. The McMaster Grading of Recommendations Assessment, Development and Evaluation (GRADE) Centre supported the guideline-development process, including performing systematic evidence reviews (up to 24 May 2019). The panel prioritized clinical questions and outcomes according to their importance to patients, as judged by the panel. The panel used the GRADE approach, including GRADE's Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subject to public comment. RESULTS: The panel agreed on 6 critical questions in managing older adults with AML, mirroring real-time practitioner-patient conversations: the decision to pursue antileukemic treatment vs best supportive management, the intensity of therapy, the role and duration of postremission therapy, combination vs monotherapy for induction and beyond, duration of less-intensive therapy, and the role of transfusion support for patients no longer receiving antileukemic therapy. CONCLUSIONS: Treatment is recommended over best supportive management. More-intensive therapy is recommended over less-intensive therapy when deemed tolerable. However, these recommendations are guided by the principle that throughout a patient's disease course, optimal care involves ongoing discussions between clinicians and patients, continuously addressing goals of care and the relative risk-benefit balance of treatment.
引用
- Sekeres MA, Guyatt G, Abel G, et al. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Adv. 2020. PMID: 32761235. doi:10.1182/bloodadvances.2020001920
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。